α7-烟碱乙酰胆碱受体在肺癌发生、发展及治疗中的作用

罗巧; 石宏; 王绍波

doi:10.12259/j.issn.2095-610X.S20220226

α7-烟碱乙酰胆碱受体在肺癌发生、发展及治疗中的作用

doi: 10.12259/j.issn.2095-610X.S20220226

罗巧¹,
石宏^2, ,,
王绍波^{1, 2, ,}

1.
云南省第一人民医院，昆明理工大学附属医院PET/CT中心，云南昆明　650100
2.
昆明理工大学灵长类转化医学研究院，云南昆明　650504

基金项目: 国家自然科学基金项目（81760306）；云南省卫生高层次人才（医学学科带头人）（D－2018011）；云南省“万人计划”青年拔尖人才项目（YNWR-QNBJ-2018-243）

详细信息

作者简介:
罗巧（1994～），女，四川遂宁人，在读硕士研究生，主要从事影像诊断工作

通讯作者:
石宏，E-mail：shih@kust.edu.cn

王绍波，E-mail：15812082912@126.com

中图分类号: R734
计量
- 文章访问数: 3467
- HTML全文浏览量: 2004
- PDF下载量: 22
- 被引次数: 0
出版历程
- 收稿日期: 2021-12-05
- 网络出版日期: 2022-02-24
- 刊出日期: 2022-03-04

Role of α7-nicotinic Acetylcholine Receptor in Occurrence，Development and Therapy of Lung Cancer

Qiao LUO¹,
Hong SHI^{2
, ,},
Shaobo WANG^{1, 2
, ,}

1.
PET/CT Center，the First People Hospital of Yunnan Province，Affiliated Hospital of Kunming University of Science and Technology Kunming Yunnan 650100
2.
Institute of Primate Translational Medicine，Kunming University of Science and Technology，Kunming Yunnan 650504，China

摘要

摘要: 烟碱乙酰胆碱受体（nAChRs）作为兴奋性和抑制性神经递质的中央调节器，控制癌细胞、癌微环境和远处转移生长因子、血管生成因子和神经营养因子的合成和释放。吸烟和其他潜在的不良环境和生活方式等因素上调nAChRs促癌作用并下调其抑癌作用。其中，α7-nAChR在肺癌细胞中高表达，并参与癌细胞的增殖、凋亡和迁移，有望成为肺癌治疗的一个新型靶点。
- α7-nAChR /
- 肺癌 /
- 靶向治疗
Abstract: Nicotinic acetylcholine receptors （nAChRs） are the central regulators of stimulatory and inhibitory neurotransmitters that control the synthesis and release of growth,angiogenic and neurotrophic factors incancer cells, the cancer microenvironment and distantmetastasis. Smoking and other possibly environmental and lifestyle factors increase the function of nAChRs that up-regulates carcinogenesis and down-regulates carcinostasis. α7-nAChRis particularly overexpressed in lung cancer cells, and participates in the proliferation, apoptosis and migration of cancer cells.Thus,α7-nAChR might be a new therapeutic target for lung cancer.
- α7-nAChR /
- Lung neoplasms /
- Molecular targeted therapy

HTML全文

参考文献(41)

[1]	Raso M G. N Bota-Rabassedas,Wistuba II Pathology and Classification of SCL[J]. C. Cancers (Basel),2021,13(4):820-831.
[2]	Pirker,R. Conquering lung cancer:current status and prospects for the future[J]. Pulmonology,2020,26(5):283-290. doi: 10.1016/j.pulmoe.2020.02.005
[3]	Sung H J, Ferlay R L, Siegel, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. 2021, 71（3）: 209-249.
[4]	Albuquerque E X,Pereira E F,Alkondon M,et al. Mammalian nicotinic acetylcholine receptors:from structure to function[J]. Physiol Rev,2009,89(1):73-120. doi: 10.1152/physrev.00015.2008
[5]	Malhotra J M,Malvezzi E,Negri,et al. Risk factors for lung cancer worldwide[J]. Eur Respir J,2016,48(3):889-902. doi: 10.1183/13993003.00359-2016
[6]	Hecht S S. Lung carcinogenesis by tobacco smoke[J]. Int J Cancer,2012,131(12):2724-2732. doi: 10.1002/ijc.27816
[7]	Cheng W L,Chen K Y,Lee K Y,et al. Nicotinic-nAChR signaling mediates drug resistance in lung cancer[J]. J Cancer,2020,11(5):1125-1140. doi: 10.7150/jca.36359
[8]	Kalamida,Avramopoulou D. Muscle and neuronal nicotinic acetylcholine receptors. Structure,function and pathogenicity[J]. FEBS J,2007,274(15):3799-3845. doi: 10.1111/j.1742-4658.2007.05935.x
[9]	Otvos R A,Still K B M,Somsen G W,et al. Drug Discovery on Natural Products:From Ion Channels to nAChRs,from Nature to Libraries,from Analytics to Assays[J]. SLAS Discov,2019,24(3):362-385.
[10]	Changeux J P. The nicotinic acetylcholine receptor:the founding father of the pentameric ligand-gated ion channel superfamily[J]. J Biol Chem,2012,287(48):40207-40215. doi: 10.1074/jbc.R112.407668
[11]	Rao V R,Perez-Neut M,Kaja S,et al. Voltage-gated ion channels in cancer cell proliferation[J]. Cancers (Basel),2015,7(2):849-875. doi: 10.3390/cancers7020813
[12]	Shapovalov G ,Ritaine A,Skryma R,et al. Role of TRP ion channels in cancer and tumorigenesis[J]. Semin Immunopathol,2016,38(3):357-369. doi: 10.1007/s00281-015-0525-1
[13]	Zoli M,Pistillo F,Gotti C. Diversity of native nicotinic receptor subtypes in mammalian brain[J]. Neuropharmacology,2015,96(Pt B):302-311.
[14]	Saigoh K Y,Yamagishi Y,Saito,et al. Abnormally high levels of oxidized DJ-1 in cases of Parkinson’s disease (PD) and dementia with lewy bodies (DLB)[J]. Journal of the Neurological Sciences,2017,381:774-775.
[15]	Bordas A,Cedillo J L,Arnalich F,et al. Expression patterns for nicotinic acetylcholine receptor subunit genes in smoking-related lung cancers[J]. J Cancer,2017,8(40):67878.
[16]	Montano-Velazquez B B,Benavides Mendez J C,Garcia-Vazquez F J,et al. Influence of Tobacco Smoke Exposure on the Protein Expression of alpha7 and alpha4 Nicotinic Acetylcholine Receptors in Squamous Cell Carcinoma Tumors of the Upper Aerodigestive Tract (Out of the Larynx)[J]. Subst Abuse,2018,12:1-5.
[17]	Moerke M J,McMahon L R,Wilkerson J L. More than Smoke and Patches:The Quest for Pharmacotherapies to Treat Tobacco Use Disorder[J]. Pharmacol Rev,2020,72(2):527-557. doi: 10.1124/pr.119.018028
[18]	Hajiasgharzadeh K, Sadigh-Eteghad S, Mansoori B, et al. Alpha7 nicotinic acetylcholine receptors in lung inflammation and carcinogenesis: Friends or foes? [J]. J Cell Physiol, 2019, 1-14.
[19]	Al-Wadei H A,Al-Wadei M H,Masi T,et al. Chronic exposure to estrogen and the tobacco carcinogen NNK cooperatively modulates nicotinic receptors in small airway epithelial cells[J]. Lung Cancer,2010,69(1):33-39. doi: 10.1016/j.lungcan.2009.09.011
[20]	Giastas P ,Zouridakis M,Tzartos S J. Understanding structure-function relationships of the human neuronal acetylcholine receptor:insights from the first crystal structures of neuronal subunits[J]. Br J Pharmacol,2018,175(11):1880-1891. doi: 10.1111/bph.13838
[21]	Whang Y M,Jo U,Sung J S,et al. Wnt5a is associated with cigarette smoke-related lung carcinogenesis via protein kinase C[J]. PLoS One,2013,8(1):e53012. doi: 10.1371/journal.pone.0053012
[22]	Dasgupta P S,Rastogi S,Pillai,et al. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways[J]. J Clin Invest,2006,116(8):2208-2217. doi: 10.1172/JCI28164
[23]	Tonini G, D’Onofrio L,Aquila Dell’ E,et al. New molecular insights in tobacco-induced lung cancer[J]. J Cancer,2013,9(5):649-655.
[24]	Xue J ,Yang S,Seng S. Mechanisms of Cancer Induction by Tobacco-Specific NNK and NNN[J]. Cancers (Basel),2014,6(2):1138-1156. doi: 10.3390/cancers6021138
[25]	Cattaneo M G,Codignola A,Vicentini L M,et al. Nicotine stimulates a serotonergic autocrine loop in human small-cell lung carcinoma[J]. J Cancer,1993,53(22):5566-5568.
[26]	Jull B,Plummer H,Schuller H J J,et al. Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway,resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells[J]. J Cancer,2001,127(12):707-717.
[27]	Gil-Ad I,Zolokov A,Lomnitski L,et al. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice[J]. J Cancer,2008,33(2):277-286.
[28]	Botello J F,Corral P,Bian T,et al. Kava and its Kavalactones Inhibit Norepinephrine-induced Intracellular Calcium Influx in Lung Cancer Cells[J]. Planta Med,2020,86(1):26-31.
[29]	Grisanti L A,Talarico J A,Carter R L,et al. beta-Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1/2 and Akt[J]. J Mol Cell Cardiol,2014,72:39-51. doi: 10.1016/j.yjmcc.2014.02.009
[30]	Munoz M, Recio S, Rosso M, et al. The antiproliferative action of [D-Arg （1）, D-Phe （5）, D-Trp （7, 9）, LEU （11）] substance P analogue antagonist against smallcell-and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist, 2015, 66（3）: 421-426.
[31]	Schuller H M. Regulatory role of the alpha7nAChR in cancer[J]. Curr Drug Targets,2012,13(5):680-687. doi: 10.2174/138945012800398883
[32]	Noguchi M,Furukawa K T,Morimoto M. Pulmonary neuroendocrine cells:physiology,tissue homeostasis and disease[J]. Dis Model Mech,2020,13(12):20-37.
[33]	Shi X ,Yao J,Wang C,et al. alpha7 nicotinic acetylcholine receptor agonist attenuated the lipopolysaccharide-induced inflammatory response via inhibiting the activation of nuclear factor-KappaB][J]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,2017,29(4):300-305.
[34]	Tan A C. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC)[J]. Thorac Cancer,2020,11(3):511-518. doi: 10.1111/1759-7714.13328
[35]	Zhou J,Kwak K J,Wu Z,et al. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway[J]. Cell Physiol Biochem,2018,47(5):1909-1924. doi: 10.1159/000491071
[36]	Pillai S,Trevino J,Rawal B,et al. beta-arrestin-1 mediates nicotine-induced metastasis through E2F1 target genes that modulate epithelial-mesenchymal transition[J]. Cancer Res,2015,75(6):1009-1020. doi: 10.1158/0008-5472.CAN-14-0681
[37]	Schuller H M. The impact of smoking and the influence of other factors on lung cancer[J]. Expert Rev Respir Med,2019,13(8):761-769. doi: 10.1080/17476348.2019.1645010
[38]	Albert-Gasco H,Ros-Bernal F,Castillo-Gomez E,et al. MAP/ERK Signaling in Developing Cognitive and Emotional Function and Its Effect on Pathological and Neurodegenerative Processes[J]. Int J Mol Sci,2020,21(12):4471-4501.
[39]	Sun X D,Li S H,Ming Dong X Y,et al. Liquid adsorption and catalytic degradation of 4-methylnitrosamino-1-3-pyridyl-1-butanone (NNK) by zeolite[J]. Microporous and Mesoporous Materials,2017,243:39-46. doi: 10.1016/j.micromeso.2017.01.041
[40]	Improgo M R,Tapper A R,Gardner P D. Nicotinic acetylcholine receptor-mediated mechanisms in lung cancer[J]. Biochem Pharmacol,2011,82(8):1015-1021. doi: 10.1016/j.bcp.2011.05.020
[41]	Wu C H,Lee C H,Ho Y S. Nicotinic acetylcholine receptor-based blockade:applications of molecular targets for cancer therapy[J]. Clin Cancer Res,2011,17(11):3533-3541. doi: 10.1158/1078-0432.CCR-10-2434

相关文章(20)

[1]	李锐成, 千红维, 范艳妮, 赵佩佩, 魏姗, 景花荣. Logistic回归和人工神经网络在鉴别诊断肺癌性胸腔积液中的应用研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241009
[2]	黄群, 侯黎莉, 王德桂, 王召君, 吴思圆, 桑莹莹. 5A模式下主动循环呼吸技术训练在肺癌手术患者中的效果, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240627
[3]	王缨, 傅聪, 傅颖. 肺癌患者血清LDH、CysC、PWR水平检测意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240424
[4]	张江, 赵喜娟, 吴江, 杨秉坤, 杨妮, 周丽萍. 肺癌放疗患者衰弱现状及影响因素分析, 昆明医科大学学报.
[5]	张洪波, 李振龙, 吕瑛, 张益绰, 裘翔铭, 黄婷婷. 单孔与双孔电视胸腔镜肺叶切除术治疗肺癌的临床疗效比较, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240419
[6]	赛亚杰, 姚吕鑫, 程玲, 沈丽, 齐彩莲, 王兆霞, 牛华涛. 确诊初期肺癌患者照顾者的负担与患者生命意义的相关性分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230906
[7]	李晨希, 查卓岑, 李娜, 罗琳, 杨扬, 陈文林. 三阳性乳腺癌的强化辅助治疗方案选择, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231020
[8]	陆小华, 袁洪新. BTLA、CTLA-4基因多态性与肝癌TACE联合靶向治疗疗效及预后相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230927
[9]	张江, 赵喜娟, 吴江, 刘燕, 李丽娟, 陈晔. 家庭赋权护理干预方案在肺癌放疗患者中的应用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211242
[10]	刘畅, 李振华, 汪颖, 阮艳琴, 曲来昊, 李定彪. 肺癌MDT联合PBL + CBL模式在临床教学中的应用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210911
[11]	宁明杰, 陈颖. 肺部微生态与肺癌的相关性研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210336
[12]	宋飞, 向盈盈, 张纪贵, 车佳音, 李林, 黄明. 经桡动脉途径与股动脉途径介入治疗肺鳞癌的对比, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210921
[13]	赵敏, 闭军强, 周永春, 张锦平, 罗镭. 9553例云南籍肺癌住院患者的疾病构成特征及变化趋势, 昆明医科大学学报.
[14]	范敏娟, 钟云华, 沈雯, 袁开芬, 赵国厚, 王蜀昆, 温林俏. 肺癌中热休克转录因子2促进热休克蛋白的表达, 昆明医科大学学报.
[15]	王洪. 前列腺素E2对COPD合并肺癌的致病机理, 昆明医科大学学报.
[16]	贺小玉. 血清高半胱氨酸蛋白61及结缔组织生长因子水平与肺癌的进展关系, 昆明医科大学学报.
[17]	潘龙芳. PDCA管理方法在肺癌患者PICC质量控制中的应用, 昆明医科大学学报.
[18]	马建强. 全胸腔镜微创肺癌根治术手术创伤的临床研究, 昆明医科大学学报.
[19]	陈锦润. 3,4-苯并芘支气管灌注构建猪肺癌模型的实验研究, 昆明医科大学学报.
[20]	陈贤玉. 曲妥珠单抗1治疗HER-2过表达乳腺癌的研究进展, 昆明医科大学学报.